Trial reportSignal transduction and targeted therapy2024
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.
NCT07150416 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
A Single-Arm Clinical Study of Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection (Gendicine) for Treatment of Multiple Ground-Glass Lung Nodules
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial.Cancer immunology, immunotherapy : CII · 2025Trial
- Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.Nature communications · 2026Article
- Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass Opacities.Cancer medicine · 2026Article
- Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response.NPJ precision oncology · 2026Article
- Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors.Biomarker research · 2026Review
- The intersection of artificial intelligence and lung nodule research: current applications and future prospects.International journal of surgery (London, England) · 2026Article
- Short-term quantitative CT changes in synchronous ground-glass nodules during immune checkpoint inhibitor therapy in patients with lung cancer.Frontiers in immunology · 2026Article
- CeRNA plays a key role in the induction of cardiovascular diseases by environmental endocrine disruptor exposure.Environmental health and preventive medicine · 2026Review
- The next generation of immunotherapies for lung cancers.Nature reviews. Clinical oncology · 2025Review
- Ablation combined with video-assisted thoracic surgery hybrid technique for multiple primary lung cancer.iScience · 2025Review
- Germline alteration analysis reveals EPHB4R91H mutation as a key player in multiple primary lung tumors.Carcinogenesis · 2025Article
- Effects of herbal medicine on clinical characteristics and biological markers in pulmonary pure ground-glass nodules: study protocol for a multicenter randomized triple-blind controlled trial.Frontiers in medicine · 2025Article
- Mindfulness-based stress reduction training and supplemented Jinshui Liujun decoction promote recovery in patients with non-small cell lung cancer.World journal of psychiatry · 2024Article
- Immunogenomic features of radiologically distinctive nodules in multiple primary lung cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Review
- Composition, functions, and applications of exosomal membrane proteins.Frontiers in immunology · 2024Review
- Exosomes in oral squamous cell carcinoma: functions, challenges, and potential applications.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 1 country.
Bo ChengDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Caichen LiDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Jianfu LiDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Longlong GongMedical Department, Genecast Biotechnology Co., Ltd, Wuxi, China.ORCID 0000-0002-5844-6078
Peng LiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Ying ChenDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Shuting ZhanDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Shan XiongDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Ran ZhongDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Hengrui LiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Yi FengDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Runchen WangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Haixuan WangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Hongbo ZhengMedical Department, Genecast Biotechnology Co., Ltd, Wuxi, China.
Jun LiuDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.ORCID 0000-0002-9001-9498
Chengzhi ZhouDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Wenlong ShaoDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Yuan QiuDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Jiancong SunDepartment of Radiation Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhanhong XieDepartment of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Zhu LiangDepartment of Cardiothoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Chenglin YangDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Xiuyu CaiDepartment of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, China.
Chunxia SuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Wei WangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Jianxing HeDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China. drjianxing.he@gmail.com.
Wenhua LiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, China. liangwh1987@163.com.
First Affiliated Hospital of Guangzhou Medical University · CNGenecast (China) · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNGuangdong Medical College · CNSun Yat-sen University · CNTongji University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein significantly improve survival in patients with advanced non-small-cell lung cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions remains unclear. This is a single-arm, phase II trial (NCT04026841) using Simon's optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients with persistent high-risk (Lung-RADS category 4 or had progressed within 6 months) GGOs. The primary endpoint was objective response rate (ORR). T/B/NK-cell subpopulations, TCR-seq, cytokines, exosomal RNA, and multiplexed immunohistochemistry (mIHC) were monitored and compared between responders and non-responders. Finally, two intent-to-treat (ITT) lesions (pure-GGO or GGO-predominant) showed responses (ORR: 5.6%, 2/36), and no patients had progressive disease (PD). No grade 3-5 TRAEs occurred. The total response rate considering two ITT lesions and three non-intent-to-treat (NITT) lesions (pure-solid or solid-predominant) was 13.9% (5/36). The proportion of CD8
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsCD8-Positive T-LymphocytesCTLA-4 AntigenCytokinesEpidermal Growth FactorHumansLungProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellTomography, X-Ray ComputedCTLA-4 AntigenCytokinesEpidermal Growth FactorProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04026841ClinicalTrials.gov
NCT07150416ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.